AU2018266131B2 - Formulation of nanostructured gels for increased agent loading and adhesion - Google Patents

Formulation of nanostructured gels for increased agent loading and adhesion Download PDF

Info

Publication number
AU2018266131B2
AU2018266131B2 AU2018266131A AU2018266131A AU2018266131B2 AU 2018266131 B2 AU2018266131 B2 AU 2018266131B2 AU 2018266131 A AU2018266131 A AU 2018266131A AU 2018266131 A AU2018266131 A AU 2018266131A AU 2018266131 B2 AU2018266131 B2 AU 2018266131B2
Authority
AU
Australia
Prior art keywords
gel
gel composition
water
triglycerol
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018266131A
Other languages
English (en)
Other versions
AU2018266131A1 (en
Inventor
Dominick J. Blasioli
Derek G. Van Der Poll
Gregory T. Zugates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alivio Therapeutics Inc
Original Assignee
Alivio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alivio Therapeutics Inc filed Critical Alivio Therapeutics Inc
Publication of AU2018266131A1 publication Critical patent/AU2018266131A1/en
Application granted granted Critical
Publication of AU2018266131B2 publication Critical patent/AU2018266131B2/en
Priority to AU2021240143A priority Critical patent/AU2021240143B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018266131A 2017-05-08 2018-05-08 Formulation of nanostructured gels for increased agent loading and adhesion Ceased AU2018266131B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021240143A AU2021240143B2 (en) 2017-05-08 2021-09-28 Formulation of nanostructured gels for increased agent loading and adhesion

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502872P 2017-05-08 2017-05-08
US62/502,872 2017-05-08
PCT/US2018/031654 WO2018208822A1 (en) 2017-05-08 2018-05-08 Formulation of nanostructured gels for increased agent loading and adhesion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021240143A Division AU2021240143B2 (en) 2017-05-08 2021-09-28 Formulation of nanostructured gels for increased agent loading and adhesion

Publications (2)

Publication Number Publication Date
AU2018266131A1 AU2018266131A1 (en) 2020-01-02
AU2018266131B2 true AU2018266131B2 (en) 2021-07-29

Family

ID=62223333

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018266131A Ceased AU2018266131B2 (en) 2017-05-08 2018-05-08 Formulation of nanostructured gels for increased agent loading and adhesion
AU2021240143A Expired - Fee Related AU2021240143B2 (en) 2017-05-08 2021-09-28 Formulation of nanostructured gels for increased agent loading and adhesion

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021240143A Expired - Fee Related AU2021240143B2 (en) 2017-05-08 2021-09-28 Formulation of nanostructured gels for increased agent loading and adhesion

Country Status (6)

Country Link
US (2) US10881745B2 (https=)
EP (1) EP3621594A1 (https=)
JP (4) JP7211974B2 (https=)
AU (2) AU2018266131B2 (https=)
CA (1) CA3061480A1 (https=)
WO (1) WO2018208822A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3136635A1 (en) * 2019-04-11 2020-10-15 Convatec Technologies Inc. Superporous hydrogels, methods of making the same, and articles incorporating the same
CN111781128B (zh) * 2020-06-15 2023-07-07 迪瑞医疗科技股份有限公司 一种尿分析仪用鞘液及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130079371A1 (en) * 2010-04-01 2013-03-28 Pharmanest Ab Bioadhesive Compositions of Local Anaesthetics
US20130280334A1 (en) * 2010-09-24 2013-10-24 Massachusetts Institute Of Technology Nanostructured Gels Capable of Controlled Release of Encapsulated Agents
US20150125403A1 (en) * 2006-02-10 2015-05-07 Dupont Tate & Lyle Bio Products Company, Llc Personal care and cosmetic compositions comprising renewably-based, biodegradable 1,3-propanediol
US20170100342A1 (en) * 2015-10-08 2017-04-13 The Brigham And Women's Hospital, Inc. Stabilized assembled nanostructures for delivery of encapsulated agents
WO2017193139A1 (en) * 2016-05-06 2017-11-09 The Brigham And Women's Hospital, Inc. Binary self assembled gels for controlled delivery of encapsulated agents to cartilage
WO2017193138A1 (en) * 2016-05-06 2017-11-09 The Brigham And Women's Hospital, Inc. Self-assembled gel for controlled delivery of thermolabile agents

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2417494A1 (fr) 1978-02-16 1979-09-14 Bottu Nouvelles compositions analgesiques et antipyretiques contenant un derive de paracetamol
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
JP3439481B2 (ja) * 1995-11-15 2003-08-25 生化学工業株式会社 光架橋ヒアルロン酸ゲルおよびその製造法
CA2212300A1 (en) 1997-08-04 1999-02-04 Abdellatif Chenite In vitro or in vivo gelfying chitosan and therapeutic uses thereof
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
FR2794998B1 (fr) 1999-06-21 2001-07-27 Oreal Organogels et leurs utilisations notamment cosmetiques
WO2003006043A1 (en) 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
US20050084470A1 (en) 2003-10-15 2005-04-21 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care and cleansing compositions containing oil seed product
CA2544814C (en) 2003-11-12 2013-05-14 Applied Nanosystems B.V. Non-symmetrical gelling agent
ES2380340T3 (es) 2003-12-05 2012-05-10 Northwestern University Anfífilos peptídicos auto-ensamblantes y métodos relacionados para la administración de factores de crecimiento
US7410950B2 (en) * 2004-04-01 2008-08-12 Board Of Regents, The University Of Texas System Peptides of CaV2.2 that inhibit pain
EP1750671B1 (en) 2004-06-03 2008-10-15 Bracco Research S.A. Liposomal assembly for therapeutic and/or diagnostic use
FR2871701B1 (fr) 2004-06-21 2006-09-22 Centre Nat Rech Scient Cnrse Biomateriaux bioactifs pour le relarguage controle de principes actifs
US7854943B2 (en) * 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
EP1800694A1 (en) 2005-12-23 2007-06-27 Applied NanoSystems B.V. Controlled release gels
EP1991688B1 (en) 2006-02-10 2019-05-01 DuPont Tate & Lyle Bio Products Company, LLC Biodegradable compositions comprising renewably-based, biodegradable 1.3-propanediol
US8968784B2 (en) 2006-05-22 2015-03-03 Research Foundation Of The City University Of New York Method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery
US20080021068A1 (en) * 2006-07-24 2008-01-24 Akorn, Inc. Aqueous gel formulation and method for inducing topical anesthesia
JP5358574B2 (ja) * 2007-08-17 2013-12-04 アルション セラピューティクス， インコーポレイテッド 高濃度の局所麻酔薬調合物
WO2009029543A1 (en) 2007-08-24 2009-03-05 Aegis Therapeutics, Llc Controlled release formulations
US20090263489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
WO2010033726A2 (en) 2008-09-17 2010-03-25 The Brigham And Women's Hospital, Inc. Drug delivery composition comprising a self-assembled gelator
JP5724108B2 (ja) * 2009-04-22 2015-05-27 メドスキン ソリューションズ ドクター ズベラック アーゲーＭｅｄＳｋｉｎ Ｓｏｌｕｔｉｏｎｓ Ｄｒ．Ｓｕｗｅｌａｃｋ ＡＧ 凍結乾燥組成物
AU2015200633A1 (en) * 2009-05-04 2015-02-26 Zars Pharma, Inc. Methods for treating pains associated with neuroma, nerve entrapment, and other conditions
CA2770490C (en) * 2009-08-11 2024-04-16 The Johns Hopkins University Compositions and methods for implantation of processed adipose tissue and processed adipose tissue products
CN102834096A (zh) * 2010-01-14 2012-12-19 卢福研究公司 用于疼痛控制的固态成型局部麻醉制剂
EP2361640A1 (en) 2010-02-25 2011-08-31 Université de Liège Cell cultivation in chitosan alginate hydrogel beads
GB201020193D0 (en) 2010-11-29 2011-01-12 Biotec Pharmacon Asa Glucan compositions
ES2390428B1 (es) * 2011-04-15 2013-10-01 Universidad De Almería Preparado de bacterias probióticas para su administración oral a peces cultivados basado en la encapsulación en hidrogeles de alginato.
CN104582826B (zh) 2012-06-25 2018-06-05 日产化学工业株式会社 分散液及水凝胶形成方法
EP2968109A2 (en) 2012-09-14 2016-01-20 Cipla Limited Topical pharmaceutical composition comprising tenofovir, an antibacterial agent and, optonally ciclopirox
EP2928513B1 (en) 2012-12-07 2018-06-06 Kansas State University Research Foundation Peptide-albumin hydrogel properties and its applications
EP2968135A4 (en) 2013-03-14 2016-10-26 Massachusetts Inst Technology INJECTABLE, MULTILAYER, SELF-COMPOSITE PEPTIDE RUBBER HYDROGELS FOR LONG-TERM AND DELAYED RELEASE OF HUMAN ANTIBODIES
US9789073B2 (en) * 2013-03-14 2017-10-17 Pathak Holdings, Llc Compositions, methods and devices for local drug delivery
US20150297731A1 (en) * 2014-04-21 2015-10-22 National Yang-Ming University Thermosensitive injectable glaucoma drug carrier gel and the fabricating method thereof
US9452178B1 (en) * 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
US20170360912A1 (en) * 2014-12-17 2017-12-21 Socovar, L.P. Chitosan-based hydrogel and applications thereof.
EP4279064A3 (en) * 2015-05-12 2024-02-28 Incept, LLC Drug delivery from hydrogels
US20180050055A1 (en) * 2016-08-16 2018-02-22 Hafiz Ahmed Exploiting nutrient deprivation for modulation of glycosylation - research diagnostic, therapeutic, and biotechnology applications
EP3335695B1 (en) * 2016-12-15 2020-02-05 UPM-Kymmene Corporation A method for freeze-drying hydrogel comprising nanofibrillar cellulose, a freeze-dried medical hydrogel comprising nanofibrillar cellulose, and a hydrogel comprising nanofibrillar cellulose

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150125403A1 (en) * 2006-02-10 2015-05-07 Dupont Tate & Lyle Bio Products Company, Llc Personal care and cosmetic compositions comprising renewably-based, biodegradable 1,3-propanediol
US20130079371A1 (en) * 2010-04-01 2013-03-28 Pharmanest Ab Bioadhesive Compositions of Local Anaesthetics
US20130280334A1 (en) * 2010-09-24 2013-10-24 Massachusetts Institute Of Technology Nanostructured Gels Capable of Controlled Release of Encapsulated Agents
US20170100342A1 (en) * 2015-10-08 2017-04-13 The Brigham And Women's Hospital, Inc. Stabilized assembled nanostructures for delivery of encapsulated agents
WO2017193139A1 (en) * 2016-05-06 2017-11-09 The Brigham And Women's Hospital, Inc. Binary self assembled gels for controlled delivery of encapsulated agents to cartilage
WO2017193138A1 (en) * 2016-05-06 2017-11-09 The Brigham And Women's Hospital, Inc. Self-assembled gel for controlled delivery of thermolabile agents

Also Published As

Publication number Publication date
JP2023041861A (ja) 2023-03-24
US20210196836A1 (en) 2021-07-01
JP7211974B2 (ja) 2023-01-24
JP2023168587A (ja) 2023-11-24
JP2020519635A (ja) 2020-07-02
AU2018266131A1 (en) 2020-01-02
US10881745B2 (en) 2021-01-05
AU2021240143B2 (en) 2023-10-19
AU2021240143A1 (en) 2021-10-28
US20180318442A1 (en) 2018-11-08
JP2022103299A (ja) 2022-07-07
CA3061480A1 (en) 2018-11-15
WO2018208822A1 (en) 2018-11-15
EP3621594A1 (en) 2020-03-18

Similar Documents

Publication Publication Date Title
AU2016335846B2 (en) Stabilized assembled nanostructures for delivery of encapsulated agents
US7875677B2 (en) Micellar drug delivery systems for hydrophobic drugs
TWI732773B (zh) 用於奈米顆粒冷凍乾燥形式的組成物及方法
US20170319500A1 (en) Self-assembled gels for controlled delivery of biologics and labile agents
US20230364014A1 (en) Self-assembled gels for controlled delivery of biologics and methods of making thereof
JP2023168587A (ja) 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
CN113613632A (zh) 麻醉剂的稳定制剂和相关剂型
HK1159493A1 (en) Solution of lipophilic substances, especially medicinal solutions
HK1159493B (en) Solution of lipophilic substances, especially medicinal solutions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired